Doximity (DOCS)
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-15
$25.81-2.20%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-15
Research Workspace
Put DOCS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 11% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 6%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 76% in its worst 12-month stretch.
View RiskDoximity's growth relies on sustaining and expanding revenue through its AI-driven platform. Revenue grew 7% year over year, and the latest quarter beat expectations. It trades at 20× P/E versus a peer median of 20×, indicating modest expectations priced in. If Doximity cuts guidance after recently raising it, that could harm credibility. Peer multiples imply a price about 11% above where it trades. This read is provisional.
Trailing returns as of 2026-09-15. DOCS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering DOCS (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for DOCS in the last 4 months.
Continue this research
Compare DOCS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DOCS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put DOCS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
CFO transition may be impacted by legal issues.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $25.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $25.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Options grant signals commitment to leadership and growth.
Advances: Sustain and grow revenue with AI-driven platform expansion
Analyst views on AI growth support revenue expansion.
Advances: Sustain and grow revenue with AI-driven platform expansion
Revenue growth exceeds expectations, supporting AI-driven expansion.
Advances: Revenue growth guidance
Beating revenue expectations supports growth guidance.
AI spending pressure indicates potential growth slowdown.
Leadership shift and AI focus could enhance growth outlook.